Current development of targeted oligonucleotide-based cancer therapies: Perspective on HER2-positive breast cancer...

Area of Science:

• Oncology
• Molecular Biology
• Biotechnology

Background:

• Non-coding oligonucleotides represent a promising therapeutic class for cancer, offering broader targetability than traditional small molecules or monoclonal antibodies.
• Oligonucleotides can target any gene involved in cancer progression or drug resistance, expanding therapeutic options.
• Small interfering RNAs (siRNAs) are particularly effective for gene silencing via RNA interference, but clinical application is limited by delivery challenges.

Purpose of the Study:

• To review nanoparticle development for systemic delivery of small interfering RNAs (siRNAs) in cancer therapy.
• To discuss criteria and considerations for creating effective siRNA delivery platforms.
• To examine the progress of siRNA-based cancer treatments in clinical trials.

Main Methods:

• Review of current literature on non-coding oligonucleotides and nanoparticle delivery systems.
• Analysis of different nanoparticle candidates for systemic siRNA delivery.
• Examination of clinical trial data for siRNA-based cancer therapeutics.

Main Results:

• Various classes of nanoparticles show potential for systemic siRNA delivery.
• Clinical trials are underway for siRNA-based cancer treatments, with some showing promise.
• HER2-positive breast cancer is highlighted as a potential beneficiary of siRNA technology.

Conclusions:

• Nanoparticle-mediated delivery is essential for the clinical success of siRNA cancer therapies.
• siRNA technology holds potential to overcome existing cancer treatment resistance.
• Further development of effective delivery platforms is critical for realizing the full therapeutic potential of siRNAs in oncology.